Search results
Despite the knock-on effects of the pandemic, there’s been a lot going on this year in the world of research! Here are snapshots of a few stories that have appeared in the Research News section of our website in 2022.
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
Information for healthcare professionals: Genetic testing and counselling in inherited retinal disease
Retina UK is delighted to announce that it has awarded three new research grants worth more than £870,000.
Retina UK aims not only to progress research along established threads, but to stimulate new thinking, encourage innovative approaches and nurture original ideas.
Jing Yu is a Research Assistant at the Nuffield Department of Clinical Neurosciences at the John Radcliffe Hospital in Oxford.
Retina UK invites applications for funding for innovative, high quality research projects investigating the causes and potential treatments for all forms of inherited retinal disease. We are particularly keen to receive proposals with demonstrable translational potential.
